CytomX Therapeutics Inc (CTMX, Financial) is set to release its Q4 2024 earnings on March 6, 2025. The consensus estimate for Q4 2024 revenue is $19.42 million, and the earnings are expected to come in at -$0.20 per share. The full year 2024's revenue is expected to be $0.12 billion, and the earnings are expected to be -$0.13 per share. More detailed estimate data can be found on the Forecast page.
CytomX Therapeutics Inc (CTMX, Financial) Estimates Trends
Revenue estimates for CytomX Therapeutics Inc (CTMX) have remained flat at $0.12 billion for the full year 2024. However, for 2025, revenue estimates have declined from $80.56 million to $76.27 million over the past 90 days. Earnings estimates for 2024 have also remained flat at -$0.13 per share, while for 2025, they have declined from -$0.46 per share to -$0.47 per share over the past 90 days.
CytomX Therapeutics Inc (CTMX, Financial) Reported History
In the previous quarter ending on September 30, 2024, CytomX Therapeutics Inc's (CTMX) actual revenue was $33.43 million, which exceeded analysts' revenue expectations of $17.51 million by 90.89%. CytomX Therapeutics Inc's (CTMX) actual earnings were $0.07 per share, which surpassed analysts' earnings expectations of -$0.17 per share by 141.42%. After releasing the results, CytomX Therapeutics Inc (CTMX) saw an increase of 9% in one day.
CytomX Therapeutics Inc (CTMX, Financial) 12 Month Price Targets
Based on the one-year price targets offered by five analysts, the average target price for CytomX Therapeutics Inc (CTMX) is $4.69, with a high estimate of $8.00 and a low estimate of $3.25. The average target implies an upside of 616.08% from the current price of $0.65.
Based on GuruFocus estimates, the estimated GF Value for CytomX Therapeutics Inc (CTMX, Financial) in one year is $2.81, suggesting an upside of 329.40% from the current price of $0.65.
Based on the consensus recommendation from seven brokerage firms, CytomX Therapeutics Inc's (CTMX, Financial) average brokerage recommendation is currently 2.1, indicating an "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
